Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
This is a commercial pre-mixed combination of BPC-157 with full-length Thymosin Beta-4 (Tβ4) — the complete 43-amino-acid actin-binding protein, not the 17–23 fragment commonly sold as TB-500. The distinction matters: TB-500 marketed by most vendors is a 7-residue synthetic fragment, whereas full-length Tβ4 is the entire human protein and is significantly more expensive to manufacture and supply.
The blend is sold by some research-peptide vendors and a small number of compounding pharmacies. Ratios vary, but a typical preparation pairs roughly equal milligram amounts of each peptide in a single vial. Marketing copy generally positions it as a "premium" alternative to the cheaper BPC-157 + TB-500 fragment blends.
History
The two components have independent histories:
- BPC-157 was characterized by Sikiric and colleagues in 1991. Almost all published evidence comes from rodent wound, tendon, and gastrointestinal models.
- Full-length Thymosin Beta-4 was isolated by the Goldstein laboratory from calf thymus in the 1980s and characterized as the principal actin-sequestering protein in mammalian cells. It has been investigated in human clinical trials by RegeneRx Biopharmaceuticals under designations such as RGN-259 for corneal wound healing and dry eye, where the program reached Phase III, and RGN-352 for cardiac repair.
The combined product appeared in research-peptide retail in the late 2010s. There is no published study evaluating the two peptides together.
Regulatory status
Neither component is approved for any indication. BPC-157 was placed in FDA 503A Category 2 in November 2023. Full-length Tβ4 has been investigational in trials sponsored by RegeneRx, including ophthalmic indications that reached late-phase testing. As of the latest publicly available regulatory information, RGN-259 has not received marketing approval. The combined blend has no regulatory standing of its own and is sold through research-chemical suppliers labeled for laboratory use only.
How researchers describe its action
The combined product has not been studied, so the action descriptions apply to the individual components:
- BPC-157 is described in preclinical work as a modulator of nitric oxide signaling and an upregulator of VEGFR2, with reported effects on tendon, gut, and vascular healing.
- Full-length Tβ4 is described as the major actin-sequestering protein in mammalian cells. Published work documents involvement in cell migration during wound healing, angiogenesis via VEGF and angiopoietin signaling, anti-inflammatory effects through NF-κB downregulation, and stimulation of progenitor-cell recruitment in cardiac repair models.
Compared with the 7-residue TB-500 fragment, full-length Tβ4 has more extensive in vivo characterization, including human safety data from RGN-259 trials. Whether co-administration with BPC-157 changes the pharmacology of either component has not been studied.
Half-life and dosing intervals
- BPC-157: approximately 15–30 minutes circulating half-life.
- Full-length Tβ4: approximately 2–3 hours circulating half-life after subcutaneous administration.
Observational protocols described in research-peptide channels typically involve subcutaneous injection once daily during an initial loading period, then a reduced maintenance schedule. Per-injection mass commonly described is in the 1–3 mg range across both peptides combined. These dosing patterns are extrapolations from published animal and Phase I-style work; they are not derived from controlled trials of the blend.
Reconstitution example
A 10 mg blend vial (5 mg BPC-157 + 5 mg Tβ4) reconstituted with 2 mL of bacteriostatic water yields a total peptide concentration of 5 mg/mL. On a 1 mL U-100 insulin syringe, 10 units (0.10 mL) delivers 0.5 mg of total peptide — 0.25 mg of each component.
Because full-length Tβ4 is significantly more expensive than TB-500 fragment, blends advertised as "BPC + TB4" warrant careful inspection of the supplier's content specification: some products labeled "TB4" in fact contain the cheaper TB-500 fragment.
What to know
- Component identity matters. Full-length Tβ4 and TB-500 fragment are different molecules. Vendor labeling is not always precise; mass-spectrometry assays confirming the full 43-residue sequence are not standard practice in research-peptide retail.
- No combined clinical data. The two-peptide blend has not been evaluated in any published trial. Full-length Tβ4 alone has human safety data from RGN-259 trials; BPC-157 does not.
- Regulatory status. BPC-157 is barred from U.S. compounding. Full-length Tβ4 is investigational and not approved.
- Storage. Refrigerate lyophilized vials. After reconstitution, refrigerate and use within the stability window suggested by the supplier.
- Reported side effects. Component user reports describe injection-site irritation and transient headaches with BPC-157; no controlled human safety profile exists for the combined blend.
Sources
- 1.Sikiric P et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157. Current Neuropharmacology.
- 2.Goldstein AL et al. (2012). Thymosin β4: a multifunctional regenerative peptide. Expert Opinion on Biological Therapy.
- 3.Crockford D (2007). Thymosin beta4 — a novel cardiovascular therapeutic. Annals of the New York Academy of Sciences.
- 4.Sosne G et al. (2010). Thymosin beta 4 promotes corneal wound healing. Annals of the New York Academy of Sciences.
- 5.FDA 503A Bulk Drug Substances list — Category 2 (November 2023, BPC-157).